Global Narcolepsy Drug Sales Market Report 2021

Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that usually last from seconds to minutes and may occur at any time. About 70% of people also experience episodes of sudden loss of muscle strength, known as cataplexy. These spells can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations while falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.
The global average price of narcolepsy drug is in the decreasing trend, from 43.3 K USD/Kg in 2012 to 35.7 K USD/Kg in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.

Market Analysis and Insights: Global Narcolepsy Drug Market
The global Narcolepsy Drug market was valued at US$ 2775.5 in 2020 and will reach US$ 5052.6 million by the end of 2027, growing at a CAGR of 10.5% during 2022-2027.

Global Narcolepsy Drug Scope and Market Size
The global Narcolepsy Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Narcolepsy Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Antioxidants
Stimulants
Others

Segment by Application
Daytime Extreme Sleepiness
Cataplexia
Others

The Narcolepsy Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Narcolepsy Drug market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Jazz Pharmaceuticals
Teva Pharmaceutical
Novartis
Mylan